Immunogenicity and protection against genital Chlamydia infection and its complications by a multisubunit candidate vaccine

Journal of Microbiology, Immunology and Infection

Volumn 40, Issue 3, 2007, Pages 188-200

  Ifere, Godwin O ^a   He, Qing ^a   Igietseme, Joseph U ^a,b   Ananaba, Godwin A ^c   Lyn, Deborah ^a   Lubitz, Werner ^d   Kellar, Kathryn L ^b   Black, Carolyn M ^b   Eko, Francis O ^a  

^a MOREHOUSE SCHOOL OF MEDICINE   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^c CLARK ATLANTA UNIVERSITY   (United States)

^d UNIVERSITY OF VIENNA   (Austria)

Author keywords

Bacterial outer membrane proteins; Bacterial vaccines; Chlamydia infections; Porins; Vaccination

Indexed keywords

BACTERIAL VACCINE; DRUG CARRIER; GAMMA INTERFERON; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G2A; MAJOR OUTER MEMBRANE PROTEIN; OUTER MEMBRANE PROTEIN; PORIN; UNCLASSIFIED DRUG; VIBRIO CHOLERA GHOST;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; C57BL 6 MOUSE; CHLAMYDIASIS; CONTROLLED STUDY; DISEASE MODEL; DRUG EFFECT; DRUG EFFICACY; EMBRYO; FEMALE; FEMALE INFERTILITY; GENITAL TRACT INFECTION; IMMUNIZATION; IMMUNOGENICITY; IMMUNOGLOBULIN PRODUCTION; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; OUTCOME ASSESSMENT; SEROTYPE; TH1 CELL; ULTRAVIOLET IRRADIATION; VAGINA; VIBRIO CHOLERAE;

ANIMALS; BACTERIAL OUTER MEMBRANE PROTEINS; BACTERIAL PROTEINS; BACTERIAL VACCINES; CHLAMYDIA INFECTIONS; CHLAMYDIA TRACHOMATIS; FEMALE; FERTILITY; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; INTERFERON TYPE II; MICE; MICE, INBRED C57BL; PORINS; VACCINATION; VACCINES, SUBUNIT; VAGINAL DISEASES;

EID: 34948841459     PISSN: 16841182     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (53)

1. Brunham RC, Zhang DJ. Transgene as vaccine for Chlamydia. Am Heart J. 1999;138:S519-22.
2. Schachter J, Grayston JT. Epidemiology of human chlamydial infections. In: Stephens RS, Byrne GI, Christiansen G, Clarke IN, Grayston JT, Rank RG, et al, eds. Chlamydial infections: Proceedings of the Ninth International Symposium on Human Chlamydial Infection 661. International Chlamydia Symposium, Berkeley, San Francisco, CA, 1998:3-10.
3. Stagg AJ. Vaccines against Chlamydia: approaches and progress. Mol Med Today. 1998;4:166-73.
4. Igietseme JU, Black CM, Caldwell HD. Chlamydia vaccines: strategies and status. BioDrugs. 2002;16:19-35.
5. Igietseme JU, Eko FO, Black CM. Contemporary approaches to designing and evaluating vaccines against Chlamydia. Expert Rev Vaccines. 2003;2:129-46.
6. Morrison RP, Caldwell HD. Immunity to murine chlamydial genital infection. Infect Immun. 2002;70:2741-51.
7. Su H, Parnell M, Caldwell HD. Protective efficacy of a parenterally administered MOMP-derived synthetic oligopeptide vaccine in a murine model of Chlamydia trachomatis genital tract infection: serum neutralizing IgG antibodies do not protect against Chlamydial genital tract infection. Vaccine. 1995;13:1023-32.
8. Johansson M, Schon K, Ward M, Lycke N. Studies in knockout mice reveal that anti-chlamydial protection requires TH1 cells producing IFN-gamma: is this true for humans? Scand J Immunol. 1997;46:546-52.
9. Johansson M, Schon K, Ward M, Lycke N. Genital tract infection with Chlamydia trachomatis fails to induce protective immunity in gamma interferon receptor-deficient mice despite a strong local immunoglobulin A response. Infect Immun. 1997; 65:1032-44.
10. Cotter TW, Ramsey KH, Miranpuri GS, Poulsen CE, Byrne GI. Dissemination of Chlamydia trachomatis chronic genital tract infection in gamma interferon gene knockout mice. Infect Immun. 1997;65:2145-52.
11. Loomis WP, Starnbach MN. T cell responses to Chlamydia trachomatis. Curr Opin Microbiol. 2002;5:87-91.
12. Morrison SG, Su H, Caldwell HD, Morrison RP. Immunity to murine Chlamydia trachomatis genital tract reinfection involves B cells and CD4+ T cells but not CDS+ T cells. Infect Immun. 2000;68:6979-87.
13. Moore T, Ananaba GA, Bolier J, Bowers S, Belay T, Eko FO, et al. Fc receptor regulation of protective immunity against Chlamydia trachomatis. Immunology. 2002;105:213-21.
14. Igietseme JU, Eko FO, He Q, Black CM. Antibody regulation of T-cell immunity: implications for vaccine strategies against intracellular pathogens. Expert Rev Vaccines. 2004;3:23-34.
15. Brunham RC, Peeling RW. Chlamydia trachomatis antigens: role in immunity and pathogenesis. Infect Agents Dis. 1994;3:218-33.
16. Batteiger BE, Rank RG, Bavoil PM, Soderberg LS. Partial protection against genital reinfection by immunization of guinea-pigs with isolated outer-membrane proteins of the chlamydial agent of guinea-pig inclusion conjunctivitis. J Gen Microbiol. 1993;139:2965-72.
17. Tuffrey M, Alexander F, Conlan W, Woods C, Ward M. Heterotypic protection of mice against chlamydial salpingitis and colonization of the lower genital tract with a human serovar F isolate of Chlamydia trachomatis by prior immunization with recombinant serovar L1 major outer membrane protein. J Gen Microbiol. 1992;138:1707-15.
18. Knight SC, Iqball S, Woods C, Stagg A, Ward ME, Tuffrey M. A peptide of Chlamydia trachomatis shown to be a primary T-cell epitope in vitro induces cell-mediated immunity in vivo. Immunology 1995;85:8-15.
19. Eko FO, Lubitz W, McMillan L, Ramey K, Moore TT, Ananaba GA, et al. Recombinant Vibrio cholerae ghosts as a delivery vehicle for vaccinating against Chlamydia trachomatis. Vaccine. 2003;21:1694-703.
20. Pal S, Theodor I, Peterson EM, de la Maza LM. Immunization with the Chlamydia trachomatis mouse pneumonitis major outer membrane protein can elicit a protective immune response against a genital challenge. Infect Immun. 2001;69:6240-7.
21. Hatch TP, Allan I, Pearce JH. Structural and polypeptide differences between envelopes of infective and reproductive life cycle forms of Chlamydia spp. J Bacteriol. 1984;157:13-20.
22. Jones RB, Batteiger BE. Human immune response to Chlamydia trachomatis infections. In: Oriel J, Ridgway G, Schachter J, Taylor-Robinson D, Ward M, eds. Chlamydial infections. London, UK: Cambridge University Press; 1986: 423-32.
23. Ward ME. Chlamydial vaccines - future trends. J Infect. 1992; 25(Suppl. 1):11-26.
24. Read TD, Brunham RC, Shen C, Gill SR, Heidelberg JF, White O, et al. Genome sequences of Chlamydia trachomatis MoPn and Chlamydia pneumoniae AR39. Nucleic Acids Res. 2000; 28:1397-406.
25. Stephens RS, Kaiman S, Lammel C, Fan J, Marathe R, Aravind L, et al. Genome sequence of an obligate intracellular pathogen of humans: Chlamydia trachomatis. Science. 1998;282:754-9.
26. Stephens RS. Chlamydial genomics and vaccine antigen discovery. J Infect Dis. 2000;181(Suppl. 3):S521-3.
27. Longbottom D, Russell M, Dunbar SM, Jones GE, Herring AJ. Molecular cloning and characterization of the genes coding for the highly immunogenic cluster of 90-kilodalton envelope proteins from the Chlamydia psittaci subtype that causes abortion in sheep. Infect Immun. 1998;66:1317-24.
28. Grimwood J, Olinger L, Stephens RS. Expression of Chlamydia pneumoniae polymorphic membrane protein family genes. Infect Immun. 2001;69:2383-9.
29. Niessner A, Kaun C, Zorn G, Speidl W, Türel Z, Christiansen G, et al. Polymorphic membrane protein (PMP) 20 and PMP 21 of Chlamydia pneumoniae induce proinflammatory mediators in human endothelial cells in vitro by activation of the nuclear factor-kappaB pathway. J Infect Dis. 2003;188:108-13.
30. Kubo A, Stephens RS. Characterization and functional analysis of PorB, a Chlamydia porin and neutralizing target. Mol Microbiol. 2000;38:772-80.
31. Kubo A, Stephens RS. Substrate-specific diffusion of select dicarboxylates through Chlamydia trachomatis PorB. Microbiology. 2001;147:3135-40.
32. Kawa DE, Stephens RS. Antigenic topology of chlamydial PorB protein and identification of targets for immune neutralization of infectivity. J Immunol. 2002;168:5184-91.
33. Kawa DE, Schachter J, Stephens RS. Immune response to the Chlamydia trachomatis outer membrane protein PorB. Vaccine. 2004;22:4282-6.
34. Eko FO, He Q, Brown T, McMillan L, Ifere GO, Ananaba GA, et al. A novel recombinant multisubunit vaccine against Chlamydia. J Immunol. 2004;173:3375-82.
35. Ramsey KH, Soderberg LS, Rank RG. Resolution of chlamydial genital infection in B-cell-deficient mice and immunity to reinfection. Infect Immun. 1988;56:1320-5.
36. Sayada C, Denamur E, Elion J. Complete sequence of the major outer membrane protein-encoding gene of Chlamydia trachomatis serovar Da. Gene. 1992;120:129-30.
37. Stothard DR, Boguslawski G, Jones RB. Phylogenetic analysis of the Chlamydia trachomatis major outer membrane protein and examination of potential pathogenic determinants. Infect Immun. 1998;66:3618-25.
38. Kalman S, Mitchell W, Marathe R, Lammel C, Fan J, Hyman RW, et al. Comparative genomes of Chlamydia pneumoniae and C. trachomatis. Nat Genet. 1999;21:385-9.
39. Eko FO, Mayr UB, Attridge SR, Lubitz W. Characterization and immunogenicity of Vibrio cholerae ghosts expressing toxin-coregulated pili. J Biotechnol. 2000;83:115-23.
40. Mermod N, Ramos JL, Lehrbach PR, Timmis KN. Vector for regulated expression of cloned genes in a wide range of gram-negative bacteria. J Bacteriol. 1986;167:447-54.
41. Eko FO, Szostak MP, Wanner G, Lubitz W. Production of Vibrio cholerae ghosts (VCG) by expression of a cloned phage lysis gene: potential for vaccine development. Vaccine. 1994; 12:1231-7.
42. Ramsey KH, Newhall WJ 5th, Rank RG. Humoral immune response to chlamydial genital infection of mice with the agent of mouse pneumonitis. Infect Immun. 1989;57:2441-6.
43. Pal S, Fielder TJ, Peterson EM, de la Maza LM. Protection against infertility in a BALB/c mouse salpingitis model by intranasal immunization with a mouse pneumonitis biovar of Chlamydia trachomatis. Infect Immun. 1994;62:3354-62.
44. Igietseme JU, Uriri IM, Kumar SN, Ananaba GA, Ojior OO, Momodu IA, et al. Route of infection that induces a high intensity of gamma interferon-secreting T cells in the genital tract produces optimal protection against Chlamydia trachomatis infection in mice. Infect Immun. 1998;66:4030-5.
45. Igietseme JU, Rank RG. Susceptibility to reinfection after a primary chlamydial genital infection is associated with a decrease of antigen-specific T cells in the genital tract. Infect Immun. 1991;59:1346-51.
46. Rank RG, Batteiger BE. Protective role of serum antibody in immunity to chlamydial genital infection. Infect Immun. 1989; 57:299-301.
47. Pal S, Peterson EM, de la Maza LM. Induction of protective immunity against a Chlamydia trachomatis genital infection in three genetically distinct strains of mice. Immunology. 2003; 110:368-75.
48. Eko FO, Schukovskaya T, Lotzmanova EY, Firstova VV, Emalyanova NV, Klueva SN, et al. Evaluation of the protective efficacy of Vibrio cholerae ghost (VCG) candidate vaccines in rabbits. Vaccine. 2003;21:3663-74.
49. Mader HJ, Szostak MP, Hensel A, Lubitz W, Haslberger AG. Endotoxicity does not limit the use of bacterial ghosts as candidate vaccines. Vaccine. 1997;15:195-202.
50. Kaisho T, Akira S. Toll-like receptors as adjuvant receptors. Biochim Biophys Acta. 2002;1589:1-13.
51. Nelson DE, Virok DP, Wood H, Roshick C, Johnson RM, Whitmire WM, et al. Chlamydial IFN-gamma immune evasion is linked to host infection tropism. Proc Natl Acad Sci USA. 2005;102:10658-63.
52. Tuffrey M, Falder P, Gale J, Taylor-Robinson D. Salpingitis in mice induced by human strains of Chlamydia trachomatis. Br J Exp Pathol. 1986;67:605-16.
53. Tuffrey M, Alexander F, Taylor-Robinson D. Severity of salpingitis in mice after primary and repeated inoculation with a human strain of Chlamydia trachomatis. J Exp Pathol (Oxford). 1990;71:403-10.